Research advances on dihydrofolate reductase inhibitors in the treatment of tumors and bacterial infections
10.16438/j.0513-4870.2023-0320
- VernacularTitle:二氢叶酸还原酶抑制剂在肿瘤和细菌感染治疗中的研究进展
- Author:
Can-tong CHEN
;
Lei HUANG
;
Ji-chen GUAN
;
Fang-fang LAI
- Publication Type:Research Article
- Keywords:
ihydrofolate reductase;
anti-tumor;
antibacterial;
ual-target;
ihydrofolate reductase inhibitor
- From:
Acta Pharmaceutica Sinica
2023;57(10):2952-2960
- CountryChina
- Language:Chinese
-
Abstract:
Dihydrofolate reductase (DHFR) is a well-known key target in the treatment of tumors, bacterial infections, and parasitic infections; and it plays a critical role in the biosynthesis of cellular DNA. DHFR inhibitors interfere with one-carbon metabolism by inhibiting substrate binding to DHFR, thereby inhibiting cell proliferation. Research on DHFR inhibitors has continued since the 1940s. To date, a variety of DHFR inhibitors have come into the market, primarily used for anti-tumor, antibacterial, antiparasitic, and anti-inflammatory therapy. This review summarizes the research progress of DHFR inhibitors with antitumor or antibacterial effects in recent years based on the classification of single-target and dual-target and looks forward to the opportunities and challenges faced by the work in this field.
